| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-11-20 | Dendritic Cell (DC) vaccines | prostate cancer |
1-2 | Medigene (Germany) | Cancer - Oncology |
| 2014-11-20 | myChoice HRD companion diagnostic and niraparib | ovarian cancer | Myriad Genetics (USA - UT) Tesaro (USA - MA) | Cancer - Oncology - Diagnostic | |
| 2014-11-20 | ISIS-STAT3Rx (AZD9150) | advanced metastatic hepatocellular carcinoma |
1b-2a | Isis Pharmaceuticals (USA), now Ionis Pharmaceuticals (USA) AstraZeneca (UK) | Cancer - Oncology |
| 2014-11-19 | BIND-014 | non-small cell lung cancer | 2 | Bind Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-11-19 | APL-130277 | Parkinson\'s disease |
2 | Cynapsus Therapeutics (Canada) | Neurodegenerative diseases |
| 2014-11-19 | Anti-Notch1 (OMP-52M51) | advanced solid tumors including HER2-negative breast cancer, esophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer, small cell lung cancer, adenoid cystic carcinoma and cholangiocarcinoma |
1a | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2014-11-18 | JVS-100 | critical limb ischemia (CLI) |
2 | Juventas Therapeutics (USA - OH) | Cardiovascular diseases |
| 2014-11-18 | eteplirsen | Duchenne Muscular Dystrophy |
3 | Sarepta Therapeutics (USA - MA) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2014-11-18 | tregalizumab (BT-061) | preclinical | Biotest (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | |
| 2014-11-18 | Debio 1347 (CH5183284) | advanced solid tumours with FGFR alterations |
1 | Debiopharm (Switzerland) | Cancer - Oncology |
| 2014-11-18 | Dx15 | thyroid cancer |
Diaxonhit (France) | Cancer - Oncology - Diagnostic | |
| 2014-11-18 | idarucizumab | rapid reversal of dabigatran-induced anticoagulation | 1 | Boehringer Ingelheim (Germany) | Cardiovascular diseases - Hematological diseases |
| 2014-11-18 | Kynamro® (mipomersen) | familial hypercholesterolemia |
3 | Genzyme (USA - MA), a Sanofi company - Isis Pharmaceuticals (USA - CA) | Cardiovascular diseases - Genetic diseases |
| 2014-11-18 | CSL112 | early recurrent cardiovascular events in post myocardial infarction patients |
CSL (Australia) | Cardiovascular diseases | |
| 2014-11-18 | OBE001 | enhancement of embryo transplantation during assisted reproductive technologies |
2 | Obseva (Switzerland) | Women health - Reproductive medicine |
| 2014-11-17 | LCZ696 | chronic heart failure with reduced ejection fraction (HF-REF) |
3 | Novartis (Switzerland) | Cardiovascular diseases |
| 2014-11-17 | Vacc-4x + Revlimid® (lenalidomide) | HIV-1 infection | 1- 2 | Bionor Pharma (Norway) Celgene (USA - NJ) | Infectious diseases |
| 2014-11-17 | mavrilimumab | rheumatoid arthritis |
2b | Medimmune (USA - MD) global biologics arm of AstraZeneca (UK) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2014-11-17 | sifalimumab | moderate to severe systemic lupus erythematosus |
2b | Medimmune (USA - MD) global biologics arm of AstraZeneca (UK) | Autoimmune diseases |
| 2014-11-17 | inclisiran (ALN-PCSsc) | hypercholesterolemia | preclinical | Alnylam Pharmaceuticals (USA - MA) | Cardiovascular diseases - Metabolic diseases |
